Pfizer Ventures led the Series B financing of Cartography Biosciences, whose lead program addresses a promising target for colorectal cancer. The startup’s drugs come from platform technologies that analyze data from healthy cells and cancer cells to identify cancer-specific targets.
In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workflows are streamlined and value is delivered across stakeholders. This will differentiate winning AI startups from incumbents and copycat competitors, said Morgan Cheatham, head of healthcare and life sciences at Breyer Capital.
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
Chirag Shah, partner at Define Ventures, thinks the success of a healthcare AI startup often depends on its ability to move beyond a narrow point solution. By integrating AI into workflows and expanding from initial “wedges” into full platforms, startups can stand out from the competition, he said.
At Epic’s annual Users Group Meeting, the EHR behemoth highlighted its growing AI strategy — announcing tools promising to benefit providers, payers and patients alike.
Smarter Technologies CEO Jeremy Delinsky explains how the company's AI infrastructure can help support health system's clinical documentation improvement efforts, ultimately strengthening RCM.
As AI chatbots become a surrogate for human connection amid a national mental health crisis, experts are worried about these tools’ lack of safeguards — with research showing the models can provide dangerous, sometimes fatal, advice. Regulators and providers alike are scrambling to catch up with a technology that evolves faster than humans are able to understand.
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
Healthcare AI progress could soon stall due to fragmented, inaccessible data systems, warned OMNY Health CEO Mitesh Rao. He said that scalable AI requires a more interoperable data infrastructure — and without it, even it will be difficult for advanced AI solutions to succeed.
Intermountain Health is deploying Layer Health’s AI engine for clinical data abstraction across several of its patient registries. The health system’s venture capital arm is also making a strategic investment in the startup.
AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.
Artificial intelligence is being incorporated into more places in healthcare, for uses such as guiding clinical trial enrollment as well as helping physicians get up to speed on a patient’s history. A panel discussed these applications and more during MedCity News’s INVEST conference in Chicago.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
To scale clinical AI, vendors must design tools that feel natural and personalized to each doctor — otherwise, clinicians won’t use them, said Heidi Health CEO Tom Kelly. In the crowded AI scribe market, he believes that clinician adoption rates, not flashy integration or deployment speeds, are the true measure of success.
Ensuring buy-in from end users is critical to hospitals’ AI success. To achieve buy-in, hospitals should start by adopting AI tools that address the problems that physicians and nurses have identified as most important to them, said Rohit Chandra, chief digital officer at Cleveland Clinic.
Without trust, the rapid adoption of AI in healthcare could stall, pointed out Joel Gordon, UW Health’s chief medical information officer. He urged healthcare leaders to focus less on flashy rollouts and more on governance, collaboration, and meaningful metrics to ensure AI delivers lasting value.
Etiome’s precision medicine approach introduces a temporal component to treating disease — drugs developed specifically to treat disease at particular points in time even before symptoms show. The Flagship Pioneering startup’s approach offers the potential to prevent disease; in cases where disease is already present, Etiome aims to halt or even reverse it.
Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.